Personalized Medicine and Epigenomics: Technologies and Global Markets

Description: This report discusses the global epigenomic market in terms of growth, size and opportunities with regard to different therapies, technologies, as well as regionally. The report includes forecasted trends and revenue through 2020.

This report provides:
- An overview of the global markets and technologies for personalized medicine and epigenomics.
- Analyses global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Analysis of the current personalized medicine business model and the commercial use of the personalized medicine technology platform.
- Evaluation of individual submarkets for personalized medicine in terms of technology, products, services, application areas and geography.
- A look at the market's dynamics, specifically growth drivers, restraints, and opportunities.
- Profiles of major players in the industry.

Study Goals and Objectives:
- Define and discuss the global market for epigenomics, including emerging opportunities in biomarkers, diagnostics and therapeutics.
- Analyze market structure by segments and subsegments.
- Estimate market revenues by regions and products.
- Identify market trends, issues and factors impacting the epigenomic market.
- Explain opportunities with respect to regions and products.
- Profile major players and analyze their core competencies and strategies.
- Track alliances, joint ventures, mergers and acquisitions, new product developments, and research and development.

Use this report to:
- Gain insight into the global market for epigenomics, including emerging opportunities in biomarkers, diagnostics and therapeutics.
- Assess global epigenomic market by types, application areas, products, segments, and regions.
- Identify market trends, issues and factors impacting the epigenomic market.

Highlights:
- The global epigenomic market reached nearly $4 billion in 2014 and $4.7 billion in 2015. The market should reach nearly $12.1 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 20.6% from 2015 to 2020.
- North America dominated the global epigenomic market and reached $1.9 billion in 2015.
- The market should reach $4.6 billion in 2020 at a CAGR of 19.9% from 2015 to 2020.
- The Asia-Pacific epigenomic market reached nearly $1.0 billion in 2015, and should reach $2.8 billion by 2020 growing at a CAGR of 22.8% throughout the period.

Intended Audience:
- Manufacturers and new entrants into the market.
- Equipment distributors, hospitals and other healthcare service providers.
- Various other life science companies.
- Research institutes, associations and academicians.

Contents:
- Chapter 1: Introduction
  - Study Goals and Objective
  - Title Description
Chapter 2: Executive Summary
- Table Summary: Global Epigenomic Market By Region, Through 2020
- Figure Summary: Global Epigenomic Market By Region, 2014-2020

Chapter 3: Market Overview
- Introduction
- New Paradigm of Epigenomics
- Diagnostics
- Drugs
- Growth Driving Forces
- Growth in Life Science Funding
- Epigenomic Map Creation
- Aging Populations in Developed Countries
- Need for Better Cancer Therapies
- Growth in Personalized Medicine
- Importance of Epigenetic Technology
- Lifecycle Status of Epigenomic Technologies

Chapter 4: Epigenetic Drugs on the Market and in the Pipeline
- Overview
- Drug Classification
- Emerging Therapies
- Large-Scale Regional Epigenomic Projects

Chapter 5: Personalized Medicine Based On Therapeutics
- Overview
- Market Dynamics
- Epigenetic Personalized Medicine for Cancer Treatment
- Epigenetic Personalized Medicine for Neurological Disorders
- Epigenetic Personalized Medicine for Cardiovascular Diseases
- Epigenetic Personalized Medicine for Others

Chapter 6: Epigenetic Therapies
- Stem Cell Therapies
- Diabetes
- Mental Disorders

Chapter 7: Biomarker Techniques
- Biomarker Discovery: DNA Methylation For Cancer Detection DNA Methylation
- Market Dynamics for Epigenetic Drugs And Biomarker Discovery

Chapter 8: Epigenetic Non-Cancer Diagnosis
- Neuro
- Research and Development
- Cardiovascular Disease
- Inflammatory and Autoimmune Disease
- Research and Development
- Figure 5: Epigenomic Analysis

Chapter 9: Epigenetic Applications
- Epigenetics During Early Embryonic Stages
- Implications Of Epigenetic Reprogramming On Animal Health And Food Consumption Risks
- Reprogramming Factors
- Epigenetic Profile Of Mesenchymal Stem Cells In Culture

Chapter 10: Epigenomics: Regional Analysis
- Overview
Chapter 11: Product Analysis
- Reagents
- Kits
- Instruments
- Enzymes
- Services

Chapter 12: Analysis By Technology
- DNA Methylation

Chapter 13: Analysis By Application
- Oncology
- Non-Oncology
- Cancer Drug Technology
- Histone Deacetylase Inhibitors
- Application Areas
- Therapy Optimization In Routine Clinical Treatment

Chapter 14: Analysis By Personalized Medicines
- Personalized Medicine For Cardiovascular Disease
- Personalized Medicine For Neurological Disorders
- Personalized Medicine For Others
- Histonic Modification As Biomarker In Cancer Detection
- Figure 31 : Global Epigenomic Market In Personalized Medicine For Cancer Treatment, 2014-2020
- Table 119 : Global Epigenomic Market In Personalized Medicine For Cancer Treatment By Region, Through 2020
- Figure 32 : Global Epigenomic Market In Personalized Medicine For Neurological Disorders, 2014-2020
- Table 120 : Global Epigenomic Market In Personalized Medicine For Neurological Disorders By Region, Through 2020

Chapter 15: Company Profiles
- Abbott Laboratories
- Affymetrix
- Agilent Technologies
- Astellas Pharmaceuticals
- BAYER AG
- Bio Vision
- Celgene Corp.
- Emd Millipore
- Epigenomics AG
- Epigentex
- Envivo Pharmaceuticals (Forum Pharmaceuticals)
- Gilead Sciences
- Glaxosmithkline
- Illumina Inc.
- Johnson & Johnson
- Karus Therapeutics Limited
- Laboratory Corp. Of America Holdings
- LES Laboratoires Servier
- Merck Sharp & Dohme
- Naturewise Biotech & Medicals Corp.
- Novartis Pharma AG
- Oncolyis Biopharma Inc.
- Orchid Chemicals & Pharmaceuticals Limited
- Progen Pharmaceuticals Limited
- Quest Diagnostics
- Roche Holding AG
- Rubicon Genomics
- Takeda Pharmaceutical Company Limited

Chapter 16: Patent Analysis
- List of Patents

List of Tables
Summary Table: Global Epigenomic Market By Region, Through 2020
Table 1: U.S. Food And Drug Administration-Approved Epigenetic Therapies
Table 2: Selected Epigenetic Therapies In Clinical Development
Table 3: Epigenetic Drug Classification With Therapeutic Potential
Table 4: Classification According To Potential Therapeutic Uses And Developmental Phases, 2005-2015
Table 5: Food And Drug Administration-Approved Epigenetic Therapies, 2004-2015
Table 6: Clinical Picture Of Personalized Medicine In Myelodysplastic Syndromes (2015)
Table 7: Epigenetic Mechanisms Implicated In Multiple Sclerosis Pathogenesis
Table 8: Global Cancer Incidences, 2012
Table 9: Major Collaborations In The Epigenetic Market, 2011-2015
Table 10: Key Global Organizations Funding Epigenomics Related R&D, 2004-2015
Table 11: Global Impact Of Cardiovascular Disease, 2013
Table 12: Indications And Outcomes
Table 13: North American Epigenomic Market By Product, Through 2020
Table 14: North American Epigenomic Market By Technology, Through 2020
Table 15: North American Epigenomic Market By Application, Through 2020
Table 16: North American Epigenomic Market By Cancer Drug Technology, Through 2020
Table 17: North American Epigenomic Market By Application Area, Through 2020
Table 18: North American Epigenetic Personalized Medicine For Cancer Treatment Market By Type, Through 2020
Table 19: North American Epigenomic Market By Segment, Through 2020
Table 20: North American Epigenomic Market For Personalized Medicine Based On Therapeutics, Through 2020
Table 21: North America Epigenetic Market For Personalized Medicine For Neurological Disorders, Through 2020
Table 22: North American Epigenetic Market For Personalized Medicine For Others, Through 2020
Table 23: North American Epigenetic Therapies Market, Through 2020
Table 24: North American Biomarker Market, Through 2020
Table 25: North American Market For Histonic Modification As Biomarker In Cancer Detection, Through 2020
Table 26: North American Epigenetic Diagnostic Market, Through 2020
Table 27: North American Epigenetic Neuro Diagnosis Market, Through 2020
Table 28: North American Epigenetic Cardiovascular Diagnosis Market, Through 2020
Table 29: North American Epigenetic Inflammatory And Autoimmune Disease Diagnosis Market, Through 2020
Table 30: North American Epigenomic Research And Development Market, Through 2020
Table 31: Asia-Pacific Epigenomic Market By Product, Through 2020
Table 32: Asia-Pacific Epigenomic Market By Technology, Through 2020
Table 33: Asia-Pacific Epigenomic Market By Application, Through 2020
Table 34: Asia-Pacific Epigenomic Market By Cancer Drug Technology, Through 2020
Table 35: Asia-Pacific Epigenomic Market By Application Area, Through 2020
Table 36: Asia-Pacific Epigenetic Market For Personalized Medicine For Cancer Treatment, Through 2020
Table 37: Asia-Pacific Epigenomic Market By Segment, Through 2020
Table 38: Asia-Pacific Epigenetic Market For Personalized Medicine By Therapeutic, Through 2020
Table 39: Asia-Pacific Epigenetic Market For Personalized Medicine For Neurological Disorders, Through 2020
Table 40: Asia-Pacific Epigenetic Market For Personalized Medicine For Others By Application, Through 2020
Table 41: Asia-Pacific Epigenetic Therapy Market By Application, Through 2020
Table 42: Asia-Pacific Biomarker Market, Through 2020
Table 43: Asia-Pacific Histonic Modification As A Biomarker In Cancer Detection Market, Through 2020
Table 44: Asia-Pacific Epigenetic Diagnosis Market, Through 2020
Table 45: Asia-Pacific Epigenetic Neuro Diagnosis Market, Through 2020
Table 46: Asia-Pacific Epigenetic Market For Cardiovascular Diagnosis, Through 2020
Table 47: Asia-Pacific Epigenetic Market For Inflammatory And Autoimmune Disease Diagnosis, Through 2020
Table 48: Asia-Pacific Epigenetic Market For Research And Development, Through 2020
Table 49: European Epigenomic Market By Product, Through 2020
Table 50: European Epigenomic Market By Technology, Through 2020
Table 51: European Epigenomic Market By Application, Through 2020
Table 52: European Epigenomic Market By Cancer Drug Technology, Through 2020
Table 53: European Epigenomic Market By Application Area, Through 2020
Table 103: Global Epigenomic Market For Reagents By Region, Through 2020
Table 104: Global Epigenomic Market For Kits By Region, Through 2020
Table 105: Global Epigenomic Market For Instruments By Region, Through 2020
Table 106: Global Epigenomic Market For Enzymes By Region, Through 2020
Table 107: Global Epigenomic Market For Services By Region, Through 2020
Table 108: Global Epigenomic Market In DNA Methylation By Region, Through 2020
Table 109: Global Epigenomic Market In Histone Methylation And Acetylation By Region, Through 2020
Table 110: Global Epigenomic Market In microRNA Modification By Region, Through 2020
Table 111: Global Epigenomic Market In Oncology By Region, Through 2020
Table 112: Global Epigenomic Market In Non-Oncology, By Region, Through 2020
Table 113: Global Epigenomic Market In DNA Methyltransferase Inhibitors By Region, Through 2020
Table 114: Global Epigenomic Market In Non-Oncology By Region, Through 2020
Table 115: Global Epigenomic Market In Diagnosis By Region, Through 2020
Table 116: Global Epigenomic Market In Prognosis By Region, Through 2020
Table 117: Global Epigenomic Market For Therapy Optimization In Routine Clinical Treatment By Region, Through 2020
Table 118: Global Epigenomic Market In Drug Discovery By Region, Through 2020
Table 119: Global Epigenomic Market In Personalized Medicine For Cancer Treatment By Region, Through 2020
Table 120: Global Epigenomic Market In Personalized Medicine For Neurological Disorders By Region, Through 2020
Table 121: Global Epigenomic Market In Personalized Medicine For Cardiovascular Disease, By Region, Through 2020
Table 122: Global Epigenomic Market In Hematological Cancers By Region, Through 2020
Table 123: Global Epigenomic Market In Solid Tumors By Region, Through 2020
Table 124: Global Epigenomic Market In Gastric Cancer By Region, Through 2020
Table 125: Global Epigenomic Market In Lung Cancer By Region, Through 2020
Table 126: Global Epigenomic Market In Huntington's Disease, By Region, Through 2020
Table 127: Global Epigenomic Market In Alzheimer's Disease By Region, Through 2020
Table 128: Global Epigenomic Market In Depression By Region, Through 2020
Table 129: Global Epigenomic Market In Mental Retardation By Region, Through 2020
Table 130: Global Epigenomic Market In Parkinson's Disease, By Region, Through 2020
Table 131: Global Epigenomic Market In Myelodysplastic Syndromes By Region, Through 2020
Table 132: Global Epigenomic Market In Obesity, By Region, Through 2020
Table 133: Global Epigenomic Market In Diabetes By Region, Through 2020
Table 134: Global Epigenomic Market In Rheumatoid Arthritis By Region, Through 2020
Table 135: Global Epigenomic Market In Multiple Sclerosis By Region, Through 2020
Table 136: Global Epigenomic Market In Inflammatory Bowel Diseases By Region, Through 2020
Table 137: Global Epigenomic Market In Lupus By Region, Through 2020
Table 138: Global Epigenomic Market In Stem Cell Therapies By Region, Through 2020
Table 139: Global Epigenomic Market In Tissue Reengineering By Region, Through 2020
Table 140: Global Epigenomic Market In Diabetes By Region, Through 2020
Table 141: Global Epigenomic Market In Rheumatoid Arthritis By Region, Through 2020
Table 142: Global Epigenomic Market In Mental Disorders By Region, Through 2020
Table 143: Global Epigenomic Market In Cardiac Dysfunction By Region, Through 2020
Table 144: Global Epigenomic Market In Cancer By Region, Through 2020
Table 145: Global Epigenomic Market In Biomarker Discovery: DNA Methylation For Cancer Detection By Region, Through 2020
Table 146: Global Epigenomic Market In Histone Modification As Biomarker In Cancer Detection By Region, Through 2020
Table 147: Global Epigenomic Market In Chromatin Remodeling By Region, Through 2020
Table 148: Global Epigenomic Market In Noncoding RNAs By Region, Through 2020
Table 149: Global Epigenomic Market In Mirnas By Region, Through 2020
Table 150: Abbott Product Portfolio
Table 151: Abbott Recent Developments
Table 152: Affymetrix Product Portfolio
Table 153: Affymetrix Recent Developments
Table 154: Agilent Product Portfolio
Table 155: Agilent's Recent Developments
Table 156: Astellas Pharmaceuticals Product Portfolio
Table 157: Astellas Pharmaceuticals Recent Developments
Table 158: Bayer Product Portfolio
Table 159: Bayer Recent Developments
Table 160: Bio Vision Product Portfolio
Table 161: Bio Vision Recent Developments
Table 162: Celgene Product Portfolio
Table 163: Emd Millipore Product Portfolio
Table 164: Emd Millipore Recent Developments
Table 165: Epigenomics Product Portfolio
Table 166: Epigenomics Recent Developments
Table 167: Epigentek Product Portfolio
Table 168: Epigentek Recent Developments
Table 169: Gilead Sciences Product Portfolio
Table 170: Gilead Sciences Recent Developments
Table 171: Glaxosmithkline Product Portfolio
Table 172: Illumina Product Portfolio
Table 173: Illumina Recent Developments
Table 174: Johnson & Johnson Product Portfolio
Table 175: Karus Therapeutics Product Portfolio
Table 176: Labcorp Product Portfolio
Table 177: Labcorp Recent Developments
Table 178: Les Laboratoires Servier Recent Developments
Table 179: Novartis Product Portfolio
Table 180: Novartis Recent Developments
Table 181: Oncolyis Biopharma Product Portfolio
Table 182: Oncolyis Biopharma Recent Developments
Table 183: Orchid Chemicals & Pharmaceuticals Product Portfolio
Table 184: Progen Pharma Product Portfolio
Table 185: Quest Diagnostics Product Portfolio
Table 186: Quest Diagnostics Recent Developments
Table 187: Roche's Product Portfolio
Table 188: Roche's Recent Developments
Table 189: Rubicon Genomics Product Portfolio
Table 190: Rubicon Genomics Recent Developments
Table 191: Takeda Pharmaceuticals Product Portfolio
Table 192: U.S. Patents, 2011-July 2015
Table 193: European And Japanese Patents, 2011-July 2015
Table 194: Japanese Patents, 2011--November 2014

List Of Figures

Summary Figure : Global Epigenomic Market By Region, 2014-2020
Figure 1 : Azac And 5-AzadC Mechanism Of Action
Figure 2 : Epigenetic Changes In Cancer Involving The Methylation Of Tumor-Suppression Genes And The Demethylation Of Prometastatic Genes
Figure 3 : Global Epigenomic Market In Personalized Medicine For Cancer Treatment, 2014-2020
Figure 4 : Population Age 65 And Older, 2010-2030
Figure 5 : Epigenomic Analysis
Figure 6 : Population Affected In High-, Middle- And Low-Income Countries By Type Of Heart Disease, 2012
Figure 7 : Global Cardiovascular Disease Percentage, 2012
Figure 8 : Epigenetic Advancement In Cardiovascular Diseases
Figure 9 : Epigenetics Mechanism
Figure 10 : North American Epigenomic Market, 2014-2020
Figure 11 : Asia-Pacific Epigenomic Market, 2014-2020
Figure 12 : Europe Epigenomic Market, 2014-2020
Figure 13 : Latin American Epigenomic Market, 2014-2020
Figure 14 : Middle East And Africa Epigenomic Market, 2014-2020
Figure 15 : Global Epigenomic Market For Reagents, 2014-2020
Figure 16 : Global Epigenomic Market For Kits, 2014-2020
Figure 17 : Global Epigenomic Market For Instruments, 2014-2020
Figure 18 : Global Epigenomic Market For Enzymes, 2014-2020
Figure 19 : Global Epigenomic Market For Services, 2014-2020
Figure 20 : Global Epigenomic Market In Dna Methylation, 2014-2020
Figure 21 : Global Epigenomic Market In Histone Methylation And Acetylation, 2014-2020
Figure 22 : Global Epigenomic Market In Microrna Modification, Through 2020
Figure 23 : Global Epigenomic Market In Oncology, 2014-2020
Figure 24: Global Epigenomic Market In Non-Oncology, 2014-2020
Figure 25: Global Epigenomic Market In DNA Methyltransferase Inhibitors, 2014-2020
Figure 26: Global Epigenomic Market In Histone Deacetylase Inhibitors, 2014-2020
Figure 27: Global Epigenomic Market In Diagnosis, 2014-2020
Figure 28: Global Epigenomic Market In Prognosis, 2014-2020
Figure 29: Global Epigenomic Market For Therapy Optimization In Routine Clinical Treatment, 2014-2020
Figure 30: Global Epigenomic Market In Prognosis, 2014-2020
Figure 31: Global Epigenomic Market In Personalized Medicine For Cancer Treatment, 2014-2020
Figure 32: Global Epigenomic Market In Personalized Medicine For Neurological Disorders, 2014-2020
Figure 33: Global Epigenomic Market In Personalized Medicine For Cardiovascular Disease, 2014-2020
Figure 34: Global Epigenomic Market In Hematological Cancers, 2014-2020
Figure 35: Global Epigenomic Market In Solid Tumors, 2014-2020
Figure 36: Global Epigenomic Market In Gastric Cancer, 2014-2020
Figure 37: Global Epigenomic Market In Lung Cancer, 2014-2020
Figure 38: Global Epigenomic Market In Huntington’s Disease, 2014-2020
Figure 39: Global Epigenomic Market In Alzheimer’s Disease, 2014-2020
Figure 40: Global Epigenomic Market In Depression, 2014-2020
Figure 41: Global Epigenomic Market In Mental Retardation, 2014-2020
Figure 42: Global Epigenomic Market In Parkinson’s Disease, 2014-2020
Figure 43: Global Epigenomic Market In Myelodysplastic Syndromes, 2014-2020
Figure 44: Global Epigenomic Market In Obesity, 2014-2020
Figure 45: Global Epigenomic Market In Diabetes, 2014-2020
Figure 46: Global Epigenomic Market In Rheumatoid Arthritis, 2014-2020
Figure 47: Global Epigenomic Market In Multiple Sclerosis, 2014-2020
Figure 48: Global Epigenomic Market In Inflammatory Bowel Diseases, 2014-2020
Figure 49: Global Epigenomic Market In Lupus, 2014-2020
Figure 50: Global Epigenomic Market In Stem Cell Therapies, 2014-2020
Figure 51: Global Epigenomic Market In Tissue Re-Engineering, 2014-2020
Figure 52: Global Epigenomic Market In Diabetes, 2014-2020
Figure 53: Global Epigenomic Market In Rheumatoid Arthritis, 2014-2020
Figure 54: Global Epigenomic Market In Mental Disorders, 2014-2020
Figure 55: Global Epigenomic Market In Cardiac Dysfunction, 2014-2020
Figure 56: Global Epigenomic Market In Cancer, 2014-2020
Figure 57: Global Epigenomic Market In DNA Methylation For Cancer Detection, 2014-2020
Figure 58: Global Epigenomic Market In Histone Modification As Biomarker In Cancer Detection, 2014-2020
Figure 59: Global Epigenomics Market In Chromatin Remodeling, 2014-2020
Figure 60: Global Epigenomic Market In Noncoding RNAs, 2014-2020
Figure 61: Global Epigenomic Market In Mirnas, 2014-2020

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3633287/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Personalized Medicine and Epigenomics: Technologies and Global Markets
- **Web Address:** http://www.researchandmarkets.com/reports/3633287/
- **Office Code:** SCDK3B8J

Product Formats
Please select the product formats and quantity you require:

- **Electronic (PDF) - Single User:**
  - **Quantity:**
  - **USD 5985**
    - **USD 6650 - Until 30th Jun 2016**

- **Electronic (PDF) - 1 - 5 Users:**
  - **Quantity:**
  - **USD 7650**
    - **USD 8500 - Until 30th Jun 2016**

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:** [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
- **First Name:** ___________________________  **Last Name:** ___________________________
- **Email Address:** * ___________________________
- **Job Title:** ___________________________
- **Organisation:** ___________________________
- **Address:** ___________________________
- **City:** ___________________________
- **Postal / Zip Code:** ___________________________
- **Country:** ___________________________
- **Phone Number:** ___________________________
- **Fax Number:** ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World